Title:
Ｂ−ＲＡＦ阻害剤及び免疫チェックポイント阻害剤を使用してがんを治療する方法
Document Type and Number:
Japanese Patent JP2018534311
Kind Code:
A
Abstract:
Ｂ−ＲＡＦ及び免疫チェックポイント阻害剤を、ＭＥＫ阻害剤とともに及び／又はＭＥＫ阻害剤なしで使用する、がんの治療のための投与レジメンを含む治療法が、本明細書において提供される。【選択図】なし
Inventors:
Colburn, Dawn
Ritchie, Nicole
Ritchie, Nicole
Application Number:
JP2018525700A
Publication Date:
November 22, 2018
Filing Date:
November 18, 2016
Export Citation:
Assignee:
Genentech, Incorporated
International Classes:
A61K45/06; A61K9/20; A61K31/437; A61K31/454; A61K39/395; A61K45/00
Other References:
PATRICK, LI LIU ET AL.: "The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination", CLINICAL CANCER RESEARCH, vol. 21, no. 7, JPN6020040426, 1 April 2015 (2015-04-01), pages 1639 - 1651, XP002746548, ISSN: 0004371132, DOI: 10.1158/1078-0432.CCR-14-2339
"A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Ze", CLINICALTRIALS.GOV ARCHIVE, JPN6020040428, 17 February 2015 (2015-02-17), ISSN: 0004371133
COOPER, ZACHARY A. ET AL.: "Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 7, JPN6020040429, 29 April 2014 (2014-04-29), pages 643 - 654, XP055345831, ISSN: 0004371134, DOI: 10.1158/2326-6066.CIR-13-0215
"A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafenib (Ze", CLINICALTRIALS.GOV ARCHIVE, JPN6020040428, 17 February 2015 (2015-02-17), ISSN: 0004371133
COOPER, ZACHARY A. ET AL.: "Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 7, JPN6020040429, 29 April 2014 (2014-04-29), pages 643 - 654, XP055345831, ISSN: 0004371134, DOI: 10.1158/2326-6066.CIR-13-0215
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation